Date: 08 Mar 2009
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Glucocorticoid treatment can alter bone metabolism, reduce bone strength, and increase the risk for osteoporotic fractures. Risk factors for glucocorticoid-induced osteoporosis (GIO) include older age, high doses, and longer duration of glucocorticoid use. The bone loss that accompanies glucocorticoid use is rapid, and early treatment with bone-sparing agents can prevent bone loss and reduce fracture risk. Several randomized controlled clinical trials have found prevention and treatment of GIO with bisphosphonates, and recently the treatment of GIO with teriparatide, to be effective. This article reviews current information on the epidemiology, pathophysiology, and clinical studies that support using bone-active agents to prevent and treat GIO.
References and Recommended Reading
Van Staa TP, Leufkens HG, Abenhaim L, et al.: Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000, 39:1383–1389.CrossRef
Yao W, Cheng Z, Busse C, et al.: Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 2008, 58:1674–1686.PubMedCrossRef
Dalle Carbonare L, Arlot ME, Chavassieux PM, et al.: Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 2001, 16:97–103.CrossRef
Recommendations for the prevention and treatment of glucocorticoids-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoids-Induced Osteoporosis [no authors listed]. Arthritis Rheum 2001, 44:1496–1503.
Buckley LM, Leib ES, Cartularo KS, et al.: Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996, 125:961–968.PubMed
Adachi JD, Bensen WG, Bianchi F, et al.: Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year follow up. J Rheumatol 1996, 23:995–1000.PubMed
Reid DM, Devogelaer J, Saag K, et al.: Effect of a single infusion of zoledronic acid 5mg versus oral risedronate 5mg on bone mineral density at lumbar spine, hip, femoral neck and trochanter in patients with glucocorticoid induced osteoporosis [abstract F403]. J Bone Miner Res 2008, 23:s122.
Delmas P, Reid I, Rizzoli R, et al.: Bone mineral density and biochemical marker response rates in postmenopausal women after treatment with zoledronic acid [abstract F401]. J Bone Miner Res 2008, 23:s121.CrossRef
Saag KM, Zanchetta JR, Devogelaer J, et al.: Teriparatide versus alendronate for treatment of glucocorticoid induced osteoporosis: 36 month results [abstract 1171]. J Bone Miner Res 2008, 23:s49.
- Glucocorticoid-induced osteoporosis
Current Osteoporosis Reports
Volume 7, Issue 1 , pp 23-26
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links